Skip to main
  1. Stocks
  2. AnaptysBio
  3. Forecast
ANAB

AnaptysBio (ANAB) Stock Forecast & Price Target

AnaptysBio (ANAB) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

AnaptysBio is supported by a strengthening Jemperli royalty stream, with global net sales of $331M in 2Q26 and $644M in 1H26, up 26% and 34% year over year, respectively, while management still expects more than $390M of annualized royalties as early as 2029. The Canadian review acceptance for rectal cancer, alongside FDA priority review and Project Orbis, validates AZUR-1’s sustained complete responses for at least 12 months and expands the path for label growth beyond endometrial cancer. Additional upside comes from Quimilza’s FDA review with a December 12, 2026 PDUFA date and from multiple late-stage readouts that could further lift long-term sales and royalty visibility.

Bears say

AnaptysBio is a clinical-stage biotechnology company whose valuation depends heavily on speculative clinical and royalty-linked upside, making it vulnerable to setbacks across both its wholly owned programs and partnered assets. The key bearish factors are failed or inconclusive Jemperli trials, ongoing litigation with GSK, and regulatory risk around new indications and the submitted BLA for imsidolimab, any of which could weaken royalty growth, remove royalty upside optionality, or force additional capital needs. With added exposure to slower Jemperli uptake, stronger PD-1/PD-L1 competition, and financial results below expectations, the stock faces significant clinical, commercial, and contractual uncertainty.

AnaptysBio (ANAB) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.

AnaptysBio (ANAB) Analyst Forecast & Price Prediction

Get the latest AnaptysBio (ANAB) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AnaptysBio (ANAB)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AnaptysBio (ANAB) Forecast

Analysts have given AnaptysBio (ANAB) a Buy based on their latest research and market trends.

According to 10 analysts, AnaptysBio (ANAB) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $76, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $76, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AnaptysBio (ANAB)


AnaptysBio (ANAB) Analyst Forecast & Price Prediction

Get the latest AnaptysBio (ANAB) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AnaptysBio (ANAB)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ANAB stock data and trends